Quantcast

Latest CancerVax Stories

2010-04-19 13:13:00

BETHESDA, Md., April 19 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that results from studies highlighting pre-clinical advances with its proprietary BiTE antibody technology were presented at the American Association for Cancer Research (AACR) Annual Meeting in Washington, DC. The Company and its collaborators reported...

2010-04-16 15:01:00

BETHESDA, Md., April 16 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that Otello Stampacchia, Ph.D., an advisor to Omega Funds, has decided not to stand for re-election at the upcoming annual meeting of stockholders, and has resigned from its board of directors effective immediately due to an increase in his duties at Omega...

2010-04-13 05:00:00

NEW YORK, April 13 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced today that the American Society of Clinical Oncology (ASCO) has accepted an abstract for oral presentation of Delcath's Phase III Trial Data comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to the best alternative care for patients with hepatic metastases from...

af6fc289ed76a9552ac60baea78b8d7b
2010-04-07 06:51:59

Rush University Medical Center leads nationwide study Rush University Medical Center is leading a nationwide Phase III clinical trial to determine whether a promising vaccine for advanced melanoma can effectively treat the deadly skin cancer. An earlier Phase II trial of the experimental drug involving 50 patients with metastatic melanoma had stunning results. Eight patients recovered completely and four partially responded to the vaccine. "Very few treatment options exist for patients with...

2010-03-24 07:45:00

BETHESDA, Md., March 24 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that the Company will participate in the 2010 Future Leaders in the Biotechnology Industry Conference, to be held on April 8, 2010 in New York City. Christian Itin, Ph.D., the Company's President and CEO, will present a 25 minute corporate overview on April 8...

2010-03-22 07:00:00

BETHESDA, Md., March 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that 11 presentations will be made by the Company and its collaborators at the American Association for Cancer Research (AACR) 101st Annual Meeting to be held April 17-21, 2010 in Washington, DC. Presentation details: Poster Title: "Validation of...

2010-03-17 09:50:00

BETHESDA, Md., March 17 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised in full their option to purchase an additional 1.5 million shares of common stock. As a result, Micromet sold a total of 11.5 million shares of its common stock at a public offering price of $7.00 per share. The Company received net proceeds from the offering of approximately $75.3...

2010-03-04 06:30:00

BETHESDA, Md., March 4 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the fourth quarter and full year ended December 31, 2009. The Company also highlighted recent pipeline progress and outlined expected 2010 milestones. "With our lead product candidate blinatumomab expected to begin a European pivotal...

2010-02-25 15:02:00

BETHESDA, Md., Feb. 25 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that the Company will participate in the 2010 RBC Capital Markets Healthcare Conference, to be held March 2 - 3, 2010 in New York City. Christian Itin, Ph.D., the Company's President and CEO, will participate in a panel discussion titled New Targets in Cancer Therapy on March 2, 2010 at 8:00 AM ET. The panel discussion will be webcast live and may be accessed at:...

2010-02-10 10:00:00

BETHESDA, Md., Feb. 10 /PRNewswire-FirstCall/ -- At its annual investor R&D Day today, Micromet, Inc. (Nasdaq: MITI) outlined the design of a registration study for the Company's lead product candidate blinatumomab in acute lymphocytic leukemia (ALL), highlighted clinical data demonstrating the breadth of blinatumomab's activity in B-cell non-Hodgkin's lymphomas and announced plans to expand clinical development of blinatumomab in the U.S. "We are very pleased with the strong support...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.